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Paulo, Brazil; and Berlin, GermanyBackground Optimal antithrombotic treatment after transcatheter aortic valve replacement (TAVR) is unknown and
determined empirically. The direct factor Xa inhibitor rivaroxaban may potentially reduce TAVR-related thrombotic
complications and premature valve failure.
Design GALILEO is an international, randomized, open-label, event-driven, phase III trial in more than 1,520 patients
without an indication for oral anticoagulation who underwent a successful TAVR (ClinicalTrials.gov NCT02556203). Patients
are randomized (1:1 ratio), 1 to 7 days after a successful TAVR, to either a rivaroxaban-based strategy or an antiplatelet-
based strategy. In the experimental arm, subjects receive rivaroxaban (10 mg once daily [OD]) plus acetylsalicylic acid (ASA,
75-100 mg OD) for 90 days followed by rivaroxaban alone. In the control arm, subjects receive clopidogrel (75 mg OD) plus
ASA (as above) for 90 days followed by ASA alone. In case new-onset atrial fibrillation occurs after randomization, full oral
anticoagulation will be implemented with maintenance of the original treatment assignment. The primary efficacy end point is
the composite of all-cause death, stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep
venous thrombosis, and systemic embolism. The primary safety end point is the composite of life-threatening, disabling, and
major bleeding, according to the Valve Academic Research Consortium definitions.
Conclusions GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of
thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended
antiplatelet therapy–based strategy in subjects without need of chronic oral anticoagulation. (Am Heart J 2016;184:81-87.)Background
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http://dx.doi.org/10.1016/j.ahj.2016.10.017United States.1 Aortic valve replacement is the most
effective treatment to alleviate symptoms and improve
survival in patients with critical aortic stenosis. Trans-
catheter aortic valve replacement (TAVR) has become the
treatment of choice among patients at prohibitive-to-high
surgical risk1-4 and a valid alternative to surgical aortic
valve replacement among patients at intermediate-to-high
surgical risk.5-8 Patients are at an increased risk of stroke
and other thromboembolic events for several months
after the TAVR procedure.9
Degenerative aortic stenosis leaflets contain large
amounts of tissue factor and thrombin, which might
contribute to the increased local inflammation and
thrombogenicity2 upon native leaflet disruption. During
the TAVR procedure, exposure of leaflet content to the
circulation with microembolization of valvular compo-
nents has been reported, with N50% of cerebral emboli
82 Windecker et al
American Heart Journal
Month 2016during TAVR reported to include thrombotic material.10
The insertion of the prosthesis without removal of the
diseased aortic valve creates an irregular blood flow zone
with the crushed native leaflets around the device
metallic frame that may predispose to thrombus forma-
tion. This prothrombotic environment associated with
platelet dysfunction and the occurrence of atrial arrhyth-
mias among other associated comorbidities may predis-
pose to thromboembolic events.
Recently, reduced leaflet motion was identified after
successful TAVR11 by computed tomography imaging as
a hemodynamically silent phenomenon, with normal
aortic valve gradients on echocardiography. A higher
incidence of cerebrovascular events was observed in
patients with possible subclinical valve thrombosis
manifesting with reduced leaflet motion.11 Reduced
leaflet motion was less frequently observed among
patients receiving oral anticoagulation (OAC) compared
with those receiving no anticoagulation. Of note,
initiation of oral anticoagulation once reduced leaflet
motion was identified resolved the condition.11 Throm-
bosis seems to be implicated in the reduced leaflet
motion condition based on the hypoattenuating opacities
observed on computed tomography analysis and on the
resolution of the condition with anticoagulation.
Currently, dual-antiplatelet therapy with acetylsalicylic
acid (ASA) and clopidogrel for 3 to 6 months (without an
indication for chronic OAC) is an empirical, widely
accepted strategy that has been incorporated into clinical
practice and relevant recommendations.12-16 However,
these recommendations lack consistency regarding
appropriate dosage and duration of therapy.15,17,18
Although it is not entirely clear whether thrombi
produced during and after TAVR have a prevailing
platelet- or thrombin-related origin, there is growing
evidence that thrombin plays a major role in the
pathophysiology of thromboembolic events. Mechanisms
of platelet activation and coagulation are highly interde-
pendent, with thrombin playing a central role in both
pathways.19 In addition, thrombin catalyzes the conver-
sion of fibrinogen into fibrin, stabilizing the acutely
formed thrombus playing a central role in arterial
thrombosis, including in patients with an acute coronary
syndrome.20 Hence, it is reasonable to consider an
antithrombotic regimen to reduce the long-term throm-
boembolic risk after TAVR.
Rivaroxaban is a non–vitamin K antagonist (VKA) oral
anticoagulant that selectively and directly inhibits factor
Xa, thereby inhibiting both thrombin formation and
endovascular thrombosis.21 Rivaroxaban was previously
demonstrated to be effective in several indications,
including the prevention of thromboembolic complica-
tions in patients with atrial fibrillation,22 the prevention
of recurrent venous thromboembolism (VTE),23 the
prevention of VTE in orthopedic surgery,24 and the
prevention of recurrent cardiac ischemic events afteracute coronary syndrome.25 This agent has the potential
to reduce the risk of thromboembolic complications after
TAVR and to optimize post-TAVR outcomes.
A strategy of rivaroxaban 10 mg once daily (OD) in
combination with ASA for the first 90 days, followed by
rivaroxaban 10 mg OD alone, might provide the best
tradeoff between efficacy and safety (bleeding) in this
population without an established indication for antic-
oagulation after TAVR. The rivaroxaban dose of 10 mg
OD is approved for the prevention of VTE in major
orthopedic surgery patients without dose adjustment in
normal to moderate renal impairment.
The GALILEO study (ClinicalTrials.gov NCT02556203)
is a multicenter, randomized, open-label, event-driven,
international phase III trial, designed to assess the efficacy
and safety of a rivaroxaban-based strategy after a
successful TAVR in comparison to the current recom-
mended antiplatelet-based strategy.12,14-16
Methods
Study objectives
The primary objective of the GALILEO trial is to
compare the efficacy of a rivaroxaban-based antithrom-
botic strategy with an antiplatelet-based antithrombotic
strategy for the prevention of death or a thromboembolic
event in patients without an indication for chronic OAC
after successful TAVR. The primary safety objective is to
compare the 2 antithrombotic strategies with regard to
life-threatening, disabling, or major bleeding according to
the Valve Academic Research Consortium (VARC-2)26
criteria.
Study population and patient selection
Approximately 1,520 men and women 18 years or
older with successful completion of a TAVR procedure
(either native valve or valve-in-valve) by iliofemoral or
subclavian access with any approved/marketed device
were eligible for enrollment. A successful TAVR26 is
defined as (1) correct positioning of a single prosthetic
heart valve into the proper anatomical location; (2)
intended performance of the prosthetic heart valve with
presence of all 3 of the following conditions post-TAVR:
(a) mean aortic valve gradient b20 mm Hg, (b) peak
transvalvular velocity b3.0 m/s, and (c) no severe or
moderate aortic valve regurgitation; and (3) absence of
periprocedural complications, such as (a) any type of
stroke, (b) VARC-2–graded life-threatening bleeding, (c)
acute coronary artery obstruction requiring intervention,
(d) major vascular complication requiring intervention
(including access-site vascular complications, any new
ipsilateral peripheral ischemia, distal embolization from a
vascular source, aortic dissection, aortic rupture, ventric-
ular perforation, cardiac tamponade, and annulus rup-
ture), (e) unresolved acute valve thrombosis, or (f) any
requirement of a repeat procedure.
Figure 1
Study flow diagram GALILEO study. Successful TAVR as defined in the “Study population and patient selection” section. * The duration of the
planned treatment period depends on the time needed to reach the efficacy cut-off date, that is, to collect the predefined number of efficacy end
points. The expected duration of the treatment is 720 days, but may be adjusted depending on the rate of subject recruitment and efficacy event
rates. On-site visits are planned at days 30, 90, and 360, and at every 180 days thereafter, and at the efficacy cut-off date. Telephone contacts are
planned at day 180, and at 30 days after the last dose intake of the study assigned medication. R, randomization.
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before or at the time of randomization, an ongoing
indication for OAC, any other indication for continued
treatment with any OAC, known bleeding diathesis,
ongoing absolute indication for dual-antiplatelet therapy
at time of screening that is unrelated to the TAVR
procedure, clinically overt stroke within the last
3 months, planned coronary or vascular intervention or
major surgery, severe renal impairment (estimated
glomerular filtration rate b30 mL/min per 1.73 m2),
dialysis, post-TAVR unresolved acute kidney injury and
moderate and severe hepatic impairment, and any
hepatic disease associated with coagulopathy. A full list
of the exclusion criteria is provided in online Supple-
mentary Table I.
Subjects provide written informed consent before
randomization.
Randomization and treatment protocol
Consenting subjects are randomized in a 1:1 ratio to a
rivaroxaban-based strategy or to an antiplatelet-based
strategy 1 to 7 days after successful TAVR and before
hospital discharge. Randomization is performed through
an InteractiveWeb Response System and stratified by site.
The study flow of the GALILEO trial is detailed in Figure 1.In subjects randomized to the rivaroxaban-based
strategy (experimental arm), rivaroxaban (10 mg OD,
taken with or without food) is started at the time of
randomization or within 1 to 3 days after last intake of
clopidogrel. Acetylsalicylic acid (75-100 mg OD) is
started immediately after randomization if not already
being taken. In subjects randomized to the
antiplatelet-based strategy (control arm), clopidogrel
75 mg OD and ASA 75-100 mg OD are continued
unchanged or to be started at the time of randomization
if not already being taken. In clopidogrel-naïve subjects, a
single loading dose of at least 300 mg is administered and
followed by clopidogrel 75 mg OD.
Under the rivaroxaban-based strategy, ASA is discon-
tinued at 90 days and rivaroxaban 10 mg OD is continued
as monotherapy. Under the antiplatelet-based strategy,
clopidogrel is discontinued at 90 days and ASA 75-100 mg
OD is continued as monotherapy. In this event-driven
study, study treatments (rivaroxaban or ASA monother-
apy) are continued until the efficacy cutoff date with an
estimated median treatment duration of 540 days, but it
may vary depending on the recruitment rate as well as on
the incidence of the primary efficacy end point.
If new-onset of atrial fibrillation (NOAF) develops,
study treatments are adapted as follows. Under the
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from 10 to 20 mg OD, or to 15 mg OD for subjects with
moderate renal impairment (ie, estimated glomerular
filtration rate b50 and≥30 mL/min per 1.73 m2). If NOAF
occurs within the first 90 days, ASA is discontinued at
90 days and either rivaroxaban is continued as mono-
therapy. Under the clopidogrel-based strategy, clopido-
grel (≤90 days) or ASA monotherapy (N90 days) is
replaced by a VKA to target an international normalized
ratio of 2 to 3. If NOAF occurs within the first 90 days,
ASA is discontinued at 90 days and VKA is continued as
monotherapy. Because these treatment adaptations are
integral parts of the study treatment regimens, events
occurring under post-NOAF study treatments are retained
in the primary study analysis (intention-to-treat). The
timing of on-site visits and/or telephone assessments are
kept unchanged until the efficacy cutoff date is reached
as described earlier.
If a subject randomized to the rivaroxaban-based
strategy needs to discontinue the assigned therapy
permanently, ASA 75-100 mg OD for the remaining
duration of the study is recommended in the absence of
an indication for full anticoagulation and if the treating
physician considers it safe and the clinical situation
allows doing so.
On-site visits are planned at days 30, 90, and 360, and at
every 180 days thereafter until the efficacy cutoff date.
Telephone contacts are planned at day 180 and at 30 days
after the last dose intake of the study assigned medica-
tion. All randomized subjects are clinically followed up
until the efficacy cutoff date irrespective of possible
deviations from the assigned treatment, and every effort
is made to complete the clinical follow-up.
Study end points
The primary efficacy end point is death or a thrombo-
embolic event, defined as the composite of all-cause
death, any stroke, myocardial infarction (MI), symptom-
atic valve thrombosis, pulmonary embolism (PE), deep
venous thrombosis (DVT), and non–central nervous
system (CNS) systemic embolism.27 The primary safety
end point is the composite of life-threatening, disabling,
or major bleeding. All components of the primary efficacy
and safety end points are blindly adjudicated by an
independent Clinical Event Committee (CEC). All-cause
death, stroke, MI, symptomatic valve thrombosis, and all
bleeding events are adjudicated according to VARC-2
definitions.26,28 Pulmonary embolism, DVT, and non-CNS
systemic embolism are adjudicated according to Buller et al.27
Secondary efficacy end points include the following:
(1) the composite of cardiovascular death, any stroke, MI,
symptomatic valve thrombosis, PE, DVT, or non-CNS
systemic embolism; and (2) the net clinical benefit,
defined as the composite of all-cause death, any stroke,
MI, symptomatic valve thrombosis, PE, DVT, non-CNS
systemic embolism, and life-threatening, disabling ormajor bleeding. Secondary safety end points include
bleeding complications according to the following
definitions: (a) composite of Thrombolysis In Myocardial
Infarction major and minor bleeding, (b) International
Society of Thrombosis and Haemostasis major bleeding,
and (c) composite of Bleeding Academic Research
Consortium scale 2, 3, or 5 bleeding. Other end points
include the separate components of the primary efficacy
and safety end points, and the mean transaortic valve
pressure gradient at approximately 360 days after ran-
domization as measured by echocardiogram.
Statistical considerations
The primary efficacy and safety analyses are conducted
on the full analysis set of all randomized patients
according to the intention-to-treat principle using end
points adjudicated by the CEC. The primary analysis
compares the time from randomization to first occur-
rence of any element of the primary composite end point
between patients randomized to the rivaroxaban regimen
vs those randomized to the antiplatelet regimen.
Follow-up is censored at the last date of known outcome
status or at the efficacy cutoff date (when 440 subjects
have experienced a positively adjudicated primary
efficacy end point), whichever comes first.
For the primary efficacy end point, the null hypothesis
is that there is no difference between randomized
treatments on the event rates over time. The
rivaroxaban-based regimen is declared superior to the
antiplatelet-based regimen if the 1-sided P value for the
log-rank test falls below .025. This testing of superiority is
hierarchically preceded by a test for noninferiority of the
rivaroxaban-based strategy vs the antiplatelet-based reg-
imen. The rivaroxaban-based regimen is declared non-
inferior to the antiplatelet regimen if the upper boundary
of the 95% CI for the hazard ratio (adapted log-rank test)
falls below 1.20. Noninferiority testing is performed on
the basis of an on-treatment analysis, in which follow-up
is censored at 2 days after permanent discontinuation of
the randomized treatment strategy. Kaplan-Meier curves
are used to describe the occurrence of the primary
efficacy end point over time. Hazard ratios and 95% CIs
are generated.
In all primary analyses, switches to full-dose antic-
oagulation are treated as an integral part of the treatment
strategy. Pre-NOAF analyses, with censoring at the time of
the switch to anticoagulation therapy, are carried out as
exploratory analyses. Post-NOAF analyses, starting at the
time of the treatment switch precipitated by NOAF, are
carried out as exploratory analyses.
The prespecified subgroup analyses include but are not
limited to gender, age, weight, body mass index, valve
type, valve-in-valve procedure, Society of Thoracic
Surgeons risk score and EuroSCORE II, renal function,
hypertension, diabetes mellitus, prior stroke or non-CNS
systemic embolism, prior MI, previous revascularization,
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frailty.
The sample size determination for the study was driven
by requirements for testing superiority of the
rivaroxaban-based strategy over the antiplatelet-based
strategy. The expected day 540 event rate of the primary
efficacy end point is 33.0%.5-7,29 The target relative risk at
day 540 is 0.80; that is, a reduction of the day 540 event
rate from 33.0% under antiplatelet-based regimen to
26.4% under the rivaroxaban-based regimen, which
corresponds to a hazard ratio of 0.7654 under an
exponential distribution. Based on these assumptions, it
was estimated that a total of 440 primary efficacy end
points would provide 80% power at a 5% significance
level. Randomization of 1,520 subjects with a minimum
follow-up of 360 days and a median of 540 days is
anticipated to allow accrual of approximately 440
primary adjudicated efficacy end points. Follow-up
continues until the target number of end points is
achieved. The Executive Committee (EC) monitors the
overall rate of the primary efficacy end points and may
alter the trial to preserve adequate power within
reasonable trial duration. An independent data safety
monitoring board (DSMB) has responsibility for monitor-
ing safety during the trial.
Substudies
Prespecified substudies that are planned in subjects
randomized in selected countries include measurement
of neurocognitive function, cerebral imaging, and imag-
ing of leaflet motion restriction.
Study organization
The trial is being conducted in 15 countries over 143
sites, in accordance with the Declaration of Helsinki,
International Conference on Harmonization, Good Clin-
ical Practice guidelines, and applicable regulatory re-
quirements. The final study protocol and informed
consent have been reviewed and approved by the ethics
boards/institutional review boards and corresponding
health authorities for all participating study sites.
GALILEO is funded by Bayer Pharma AG and Janssen
Pharmaceuticals. The executive committee is composed
of members of the academic leadership of the trial and
members from each sponsoring company. The academic
leadership of the trial came forth from a partnership
between Mount Sinai and European Cardiovascular
Research Institute, which designed the GALILEO in
cooperation with the trial sponsors. The EC provides
oversight of trial conduct and data analysis and oversees
publication. Data analyses will be conducted by Cardia-
lysis with validation by the trial sponsor. The academic
leadership partners will have free and complete access to
all trial data and will submit these results for publication
in a peer-reviewed medical journal. The steering com-
mittee composed of academic experts and National LeadInvestigators (online supplement) is responsible for the
implementation of the protocol.
The DSMB is composed of 3 members (online
supplement) who are not directly involved in the
conduct of the trial. The DSMB will review the study
(including reported serious adverse events) on a periodic
basis, as detailed in the DSMB charter, and provides
recommendations to the EC. An independent, blinded
CEC applies the protocol definitions as detailed in the
CEC charter and adjudicates all suspected study end
points.
Conclusion
GALILEO is the first randomized clinical trial of an
optimized direct acting OAC-based antithrombotic regimen
after TAVR. The first patientwas enrolled inDecember 2015,
and 362 patients have been enrolled untilmid-October 2016.
GALILEO will provide randomized evidence of the efficacy
and safety of a rivaroxaban-based strategy comparedwith an
antiplatelet-based regimen after successful TAVR in the
absence of an established indication for OAC.
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